These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35044481)

  • 1. [Relevance of COMT inhibitors in the treatment of motor fluctuations].
    Jost WH; Buhmann C; Classen J; Eggert K; Kohl Z; Outeiro T; Tönges L; Woitalla D; Reichmann H
    Nervenarzt; 2022 Oct; 93(10):1035-1045. PubMed ID: 35044481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
    Wu W; Lu X; Zhang L; Hong D
    Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
    Harrison-Jones G; Marston XL; Morgante F; Chaudhuri KR; Castilla-Fernández G; Di Foggia V
    Eur J Neurol; 2023 Oct; 30(10):3132-3141. PubMed ID: 37489574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
    Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
    Expert Opin Pharmacother; 2022 Jul; 23(10):1123-1128. PubMed ID: 35373688
    [No Abstract]   [Full Text] [Related]  

  • 11. The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.
    Leta V; van Wamelen DJ; Aureli F; Metta V; Trivedi D; Cortelli P; Rodriguez-Blazquez C; Rizos A; Ray Chaudhuri K
    J Neural Transm (Vienna); 2023 Jul; 130(7):925-930. PubMed ID: 37036498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
    Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
    J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):3-5. PubMed ID: 33646998
    [No Abstract]   [Full Text] [Related]  

  • 16. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
    Linazasoro-Cristóbal G; López Del Val LJ; García Ruiz-Espiga P; López-Manzanares L; Luquin-Piudo MR; Martínez-Castrillo JC; Mir P; Pagonabarraga-Mora J
    Rev Neurol; 2020 Jun; 70(s01):S1-S11. PubMed ID: 32515486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
    Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.